Preclinical studies have shown that ARID1A deficiency sensitizes CRC cells to PARP inhibitors (olaparib, rucaparib, veliparib, or BMN673) in vitro and in vivo.33 The gene discussed is ARID1A; the disease is colorectal carcinoma.